ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN LUX-LUNG 3, A PHASE III TRIAL OF AFATINIB OR CISPLATIN/PEMETREXED IN EGFR MUTATION-POSITIVE LUNG CANCER
Other conference paper


Full Text

Times Cited
Web of Science3WOS source URL (as at 18/09/2021) Click here for the latest count

Other information
All Author(s) ListYang JC, Schuler M, Yamamoto N, O'Byrne KJ, Hirsh V, Mok TSK, Massey D, Zazulina V, Shahidi M, Sequist LV
Name of Conference37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Start Date of Conference28/09/2012
End Date of Conference02/10/2012
Place of ConferenceVienna
Country/Region of ConferenceAustria
Journal nameAnnals of Oncology
Detailed descriptionorganized by European Society for Medical Oncology,
Year2012
Month9
Day1
Volume Number23
PublisherOxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
Pages410 - 411
ISSN0923-7534
eISSN1569-8041
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-18-09 at 23:48